Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months

Probiotics and Antimicrobial Proteins

Volumn 8, Issue 3, 2016, Pages 130-133

  Davar, Robab ^a   Nokhostin, Fahimeh ^a   Eftekhar, Maryam ^a   Sekhavat, Leili ^a   Bashiri Zadeh, Mohammad ^b   Shamsi, Farimah ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Industrial Engineering   (Iran)

Author keywords

Probiotic; Recurrence; Vulvovaginal candidiasis

Indexed keywords

FLUCONAZOLE; PROBIOTIC AGENT; ANTIFUNGAL AGENT;

ADULT; ARTICLE; BIFIDOBACTERIUM; CONTROLLED STUDY; ERYTHEMA; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINAL BURNING SENSATION; VAGINAL PRURITUS; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; HUMANS; PROBIOTICS; TREATMENT OUTCOME;

EID: 84969799423     PISSN: 18671306     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12602-016-9218-x     Document Type: Article

References (13)

1. Geiger AM, Foxman B, Gillespie BW (1995) The epidemiology of vulvovaginal candidiasis among university students. Am J Public Health 85:1146. doi:10.2105/AJPH.85.8_Pt_1.1146
2. Geiger AM, Foxman B (1996) Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 7:182. doi:10.1097/00001648-199603000-00013
3. Hurley R, De Louvois J (1979) Candida vaginitis. Postgrad Med J 55:645. doi:10.1097/00001648-199603000-00013
4. Sobel JD (1985) Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152:924. doi:10.1016/s0002-9378(85)80003-x
5. Houang ET, Chappatte O, Byrne D et al (1990) Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 34:909. doi:10.1128/aac.34.5.909
6. Iannitti T, Palmieri B (2010) Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 29:701–725. doi:10.1016/j.clnu.2010.05.004
7. Sobel JD et al (2004) Maintenance fluconazole therapy for recurrent vulvovaginalcandidiasis. N Engl J Med 351:876–883. doi:10.1056/nejmoa033114
8. Reid G et al (2003) Oral use of lactobacillus rhamnosus GR-1 and lactobacillus fermentum RC-14 significantly alters vaginal flora. FEMS Immunol Med Microbiol 35:131–134. doi:10.1016/s0928-8244(02)00465-0
9. Ramezanzade F (2001) Survey and compare with treatment and recurrence of VVC. Hakim J 103–108
10. Mendeling W et al (2004) Copering efficacy and tolerability of typical combination therapy with clotrimazol and single dose fluconazole in vulvovaginalmycoses. Mycoses 47:136–142. doi:10.1111/j.1439-0507.2004.00970.x
11. Ehrstrom S, Daroczy K, Rylander E, Samuelsson C, Johannesson U et al (2010) Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 12:691–699. doi:10.1016/j.micinf.04.010
12. Martinez RCR et al (2009) Improved treatment of vulvovaginitis candidiasis with fluconazole plus probiotic lactobacillus rhamnosus GR-1 and lactobacillus reuteri RC-14. Soc Appl Microbiol 48:269–274. doi:10.1111/j.1472-765x.2008.02477.x
13. Kingsley C et al (2009) Oral use of probiotic as an adjunctive theropy to fluconazole in the treatment of yeast vaginitis. Microbial Ecol Health Dis 21:72–77. doi:10.1080/08910600902907475